Fairfield, Bush & Co’s 2seventy bio TSVT Stock Holding History

Fairfield, Bush & Co’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-666	Closed	-$6.74K	–	476
2023 Q2	$6.74K	Buy	+666	New	+$7.05K	﹤0.01%	358

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Fairfield, Bush & Co's TSVT Position: Q3 2023 in Review

Fairfield, Bush & Co sold out of 2seventy bio (TSVT) in Q3 2023, closing a stake of 666 shares — an estimated $6.74K sold.

Fairfield, Bush & Co first reported a position in TSVT in Q2 2023 and held it in 1 quarter. The position peaked at $6.74K in Q2 2023. 145 funds tracked by Wall St. Rank hold TSVT as of Q3 2023.

Fairfield, Bush & Co reported no remaining 2seventy bio position as of Q3 2023 after selling out during the quarter.
Fairfield, Bush & Co sold 666 2seventy bio shares in Q3 2023, an estimated $6.74K.
Fairfield, Bush & Co first reported a position in 2seventy bio in Q2 2023 and held it in 1 quarter.
Fairfield, Bush & Co's 2seventy bio position peaked at $6.74K in Q2 2023.
145 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2023.

Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.